Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Retained Earnings (2016 - 2025)

Altimmune (ALT) has disclosed Retained Earnings for 16 consecutive years, with -$649.5 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 12960.18% to -$649.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$649.5 million through Dec 2025, down 12960.18% year-over-year, with the annual reading at -$649.5 million for FY2025, 12960.18% down from the prior year.
  • Retained Earnings for Q4 2025 was -$649.5 million at Altimmune, down from -$5.0 million in the prior quarter.
  • The five-year high for Retained Earnings was -$4.8 million in Q3 2024, with the low at -$649.5 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$148.8 million, with a median of -$5.2 million recorded in 2022.
  • Peak annual rise in Retained Earnings hit 98.98% in 2025, while the deepest fall reached 12960.18% in 2025.
  • Over 5 years, Retained Earnings stood at -$5.0 million in 2021, then fell by 3.71% to -$5.2 million in 2022, then rose by 4.27% to -$5.0 million in 2023, then increased by 0.62% to -$5.0 million in 2024, then tumbled by 12960.18% to -$649.5 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$649.5 million, -$5.0 million, and -$5.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.